<?xml version="1.0" encoding="UTF-8"?>
<compound>
  <id type="integer">3146</id>
  <title>T3D3104</title>
  <common-name>Difenacoum</common-name>
  <description>Difenacoum is an anticoagulant and rodenticide derived from coumarin. (A365)</description>
  <cas>56073-07-5</cas>
  <pubchem-id>41735</pubchem-id>
  <chemical-formula>C31H24O3</chemical-formula>
  <weight>444.172550</weight>
  <appearance>White powder.</appearance>
  <melting-point>216°C</melting-point>
  <boiling-point nil="true"/>
  <density nil="true"/>
  <solubility>3.1e-05 mg/mL at 20°C [TOMLIN,C (1997); pH 5.2]</solubility>
  <specific-gravity nil="true"/>
  <flash-point nil="true"/>
  <vapour-pressure nil="true"/>
  <route-of-exposure>Oral (ingestion) (L1817) ; dermal (L1817)</route-of-exposure>
  <target nil="true"/>
  <mechanism-of-toxicity>Difenacoum inhibits the enzyme Vitamin K epoxide reductase. This enzyme is needed for the reconstitution of the vitamin K in its cycle from vitamin K-epoxide, and so difenacoum steadily decreases the level of active vitamin K in the blood. Vitamin K is required for the synthesis of important substances including prothrombin, which is involved in blood clotting. This disruption becomes increasingly severe until the blood effectively loses any ability to clot. In addition, difenacoum increases permeability of blood capillaries. The blood plasma and blood itself begins to leak from the blood vessels, causing internal bleeding leading to shock, loss of consciousness, and eventually death. (L1257)</mechanism-of-toxicity>
  <metabolism nil="true"/>
  <toxicity>LD50: 0.8 mg/kg (Oral, Mouse) (T80)
LD50: 50 mg/kg (Dermal, Rat) (T80)</toxicity>
  <lethaldose nil="true"/>
  <carcinogenicity>No indication of carcinogenicity to humans (not listed by IARC).</carcinogenicity>
  <use-source>Difenacoum is a rodenticide. (L1252)</use-source>
  <min-risk-level nil="true"/>
  <health-effects>Difenacoum is an anticoagulant and causes internal bleeding, leading to shock, loss of consciousness, and eventually death. (L1257)</health-effects>
  <symptoms>Difenacoum initially causes dehydration before progressing to bleeding complications. (L1257)</symptoms>
  <treatment>The primary antidote to difenacoum poisoning is immediate administration of vitamin K1 (initially slow intravenous injections of 10-25 mg repeated all 3-6 hours until normalisation of the prothrombin time; then 10 mg orally four times daily as a "maintenance dose"). It is an extremely effective antidote, provided the poisoning is caught before too much damage has been done to the victim's circulatory system. At high doses  difenacoum can affect the body for many months, and the antidote must be administered regularly for a long period of time. (L1257)</treatment>
  <created-at type="dateTime">2009-07-23T18:26:18Z</created-at>
  <updated-at type="dateTime">2026-04-03T01:25:00Z</updated-at>
  <interacting-proteins nil="true"/>
  <wikipedia nil="true"/>
  <uniprot-id nil="true"/>
  <kegg-compound-id>C16807</kegg-compound-id>
  <omim-id></omim-id>
  <chebi-id></chebi-id>
  <biocyc-id></biocyc-id>
  <ctd-id nil="true"/>
  <stitch-id>Difenacoum</stitch-id>
  <drugbank-id nil="true"/>
  <pdb-id nil="true"/>
  <actor-id>15188</actor-id>
  <organism nil="true"/>
  <export type="boolean">true</export>
  <metabolizing-proteins nil="true"/>
  <transporting-proteins nil="true"/>
  <moldb-smiles>OC1=C(C2CC(CC3=CC=CC=C23)C2=CC=C(C=C2)C2=CC=CC=C2)C(=O)C2=CC=CC=C2O1</moldb-smiles>
  <moldb-formula>C31H24O3</moldb-formula>
  <moldb-inchi>InChI=1S/C31H24O3/c32-30-26-12-6-7-13-28(26)34-31(33)29(30)27-19-24(18-23-10-4-5-11-25(23)27)22-16-14-21(15-17-22)20-8-2-1-3-9-20/h1-17,24,27,33H,18-19H2</moldb-inchi>
  <moldb-inchikey>NZOWVZVFSVRNOR-UHFFFAOYSA-N</moldb-inchikey>
  <moldb-average-mass type="decimal">444.5205</moldb-average-mass>
  <moldb-mono-mass type="decimal">444.172544634</moldb-mono-mass>
  <origin>Exogenous</origin>
  <state>Solid</state>
  <logp nil="true"/>
  <hmdb-id nil="true"/>
  <chembl-id nil="true"/>
  <chemspider-id>38081</chemspider-id>
  <structure-image-file-name nil="true"/>
  <structure-image-content-type nil="true"/>
  <structure-image-file-size type="integer" nil="true"/>
  <structure-image-updated-at type="dateTime" nil="true"/>
  <biodb-id nil="true"/>
  <synthesis-reference></synthesis-reference>
  <structure-image-caption nil="true"/>
  <chemdb-id>CHEM002438</chemdb-id>
  <dsstox-id>DTXSID2058128</dsstox-id>
  <toxcast-id nil="true"/>
  <stoff-ident-origin nil="true"/>
  <stoff-ident-id nil="true"/>
  <susdat-id>NS00015683</susdat-id>
  <iupac nil="true"/>
  <moldb-polar-surface-area>46.53</moldb-polar-surface-area>
  <moldb-refractivity>143.7881</moldb-refractivity>
  <moldb-polarizability>50.63775519780212</moldb-polarizability>
  <moldb-rotatable-bond-count>3</moldb-rotatable-bond-count>
  <moldb-acceptor-count>3</moldb-acceptor-count>
  <moldb-donor-count>1</moldb-donor-count>
  <moldb-pka-strongest-acidic>8.194762244174761</moldb-pka-strongest-acidic>
  <moldb-pka-strongest-basic>-5.523886162480479</moldb-pka-strongest-basic>
  <moldb-physiological-charge>0</moldb-physiological-charge>
  <moldb-number-of-rings>6</moldb-number-of-rings>
  <moldb-alogps-logp>6.92</moldb-alogps-logp>
  <moldb-alogps-logs>-6.83</moldb-alogps-logs>
  <moldb-alogps-solubility>6.55e-05 g/l</moldb-alogps-solubility>
</compound>
